Purpose Diabetic peripheral neuropathy (DPN) is the commonest cause of neuropathy
worldwide, and its prevalence increases with the duration of diabetes. It affects …

There is a high prevalence of painful diabetic polyneuropathy (pDPN) with around one-third
of all patients with diabetes suffering from pDPN. pDPN has debilitating consequences, with …

Although recent scientific advances have improved our understanding of basic biological
mechanisms underlying chemotherapy-induced peripheral neuropathy (CIPN), few …

Background: A sedentary lifestyle and an unhealthy diet have considerably increased the
incidence of diabetes mellitus worldwide in recent decades, which has generated a high …

Background Diabetic peripheral neuropathy (DPN) is a common and severe complication
that affects 50% of people with diabetes. Painful DPN is reported to occur in 16% to 24% of …

Purpose Diabetic peripheral neuropathy (DPN) is the most common complication of
diabetes. Small and large peripheral nerve fibers can be involved in DPN. Large nerve fiber …

Pregabalin is a first-line treatment in all major international guidelines on the management
of painful diabetic neuropathy (pDPN). Treatment with pregabalin leads to a clinically …

Diabetes mellitus remains a public health problem, affecting 422 million people worldwide.
Currently, there is no consensus around treating painful diabetic peripheral neuropathy in a …

Management of neuropathic pain in people with diabetes has been widely investigated.
However, little attention was paid to address ischemic‐related pain in patients with diabetes …

The traditional system of medicine has shown much better improvement, less side effect,
and less expensive as compared to modern synthetic drugs in the treatment of diabetes …